Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure

Journal of B.U.ON.

Volumn 16, Issue 1, 2011, Pages 80-83

  Alkis, N ^a   Demirci, U ^b   Benekli, Mustafa ^b   Yilmaz, U ^c   Isikdogan, A ^d   Sevinc, A ^e   Ozdemir, N Y ^f   Koca, D ^c   Yetisyigit, T ^a   Kaplan, M A ^d   Uncu, D ^f   Unek, T ^c   Gumus, M ^g  

^a Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d DICLE UNIVERSITY   (Turkey)

^e GAZIANTEP UNIVERSITY   (Turkey)

^f NONE   (Turkey)

^g DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Fluoropyrirnidines; Metastatic colorectal cancer; Mitomycin C; Salvage therapy

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; UFT;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LIVER METASTASIS; LIVER TOXICITY; LUNG METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; TEGAFUR; URACIL;

EID: 79954507349     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 57: 71-96.
2. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306: 752-756.
3. Saltz L, Cox J, Blanke C et al. Irinotecan Study Group: Irinotecan plus fluorouracil for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
4. Goldberg R, Sargent D, Morton R et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30. (Pubitemid 41095110)
5. Yaman E, Uner A, Er O et al. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer. Med Oncol 2007; 24: 431-435. (Pubitemid 350135937)
6. Yildiz R, Buyukberber S, Uner A et al. Bevaciz umab plus irinotecan-based therapy in metastatic colorectal cancer patients previously treated with oxaliplatin-based regimens. Cancer Invest 2010; 28: 33-37.
7. Punt C. New drugs in the treatment of colorectal carcinoma. Cancer 1998; 83: 679-689. (Pubitemid 28387690)
8. Tomasz M. Mitomycin C: small, fast and deadly (but very selective). Chem Biol 1995; 2: 575-579.
9. Bradner WT. Mitomycin C: a clinical update. Cancer Treat Rev 2001; 27: 35-50.
10. Sartorelli AC, Booth BA. The synergistic anti-neoplastic activity of combinations of mitomycin with either 6-thioguanine or 5-fluorouracil. Cancer Res 1965; 25: 1393-1400.
11. Rusello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A. Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon cancer cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol 1989;25:571-572. (Pubitemid 19061781)
12. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 ). Eur J Cancer 2009; 45: 228-247.
13. National Cancer Institute Common Toxicity Criteria (NCI-CTC) v2.0. [http://ctep.info.nih.gov/reporting/ctc.html].
14. Aphinives P, Bhudhisawasdi V, Sae-Seow O, Uttaravichien T. 5-fluorouracil and mitomycin-C: effective, low-cost chemotherapy for colorectal cancer. J Med Assoc Thai 2006; 89: 1885-1889. (Pubitemid 44916110)
15. Seitz JF, Perrier H, Giovannini M, Capodano G, Bemardini D, Bardou VJ. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother 1998; 10: 258-265. (Pubitemid 28302667)
16. Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995; 75: 769-774.
17. Ross P, Norman A, Cunningham D et al. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997; 8: 995-1001. (Pubitemid 27475731)
18. Ikeda E, Kodaira S, Teramoto T et al. Optimal dosage of UFT + MMC combination chemotherapy for advanced colorectal cancer-phase I/II study of combination chemotherapy of MMC with 2-week intervals and intermittent UFT administration-Study Group of UFTM Therapy for Advanced Colorectal Cancer. Gan To Kagaku Ryoho 1996; 23: 1291-1298. (Pubitemid 26342239)
19. Gyldenkeme N, Glimelius B, Frodin JE et al. A phase II study of UFT and leucovorin in combination with mitomycin C in patients with metastatic colorectal cancer. Acta Oncol 2004; 43: 276-279. (Pubitemid 38757049)
20. Vormittag L, Kornek GV, Gruhsmann B et al. UFT/leucovorin and mitomycin C as salvage treatment in patients with advanced colorectal cancer - a retrospective analysis. Anticancer Drugs 2007; 18: 709-712. (Pubitemid 47343665)